Does MDwise Cover Cialis?

Why MDwise Excludes Most Erectile Dysfunction Drugs

Federal Medicaid policy, not MDwise itself, drives this exclusion. The Deficit Reduction Act of 2005 explicitly permits state Medicaid programs to exclude drugs used for erectile dysfunction from their formularies [1]. Indiana's Medicaid program follows this federal guidance, and MDwise, as a contracted managed care entity, implements these restrictions across its Hoosier Healthwise and HIP membership.

The Federal Exclusion Explained

Section 1927(d)(2) of the Social Security Act lists ED medications among the categories that states may exclude from Medicaid coverage [2]. This means MDwise has no obligation to cover Cialis, Viagra, Levitra, or their generic equivalents when prescribed solely for sexual dysfunction. The exclusion applies regardless of whether the prescriber documents medical necessity.

How MDwise Formulary Decisions Work

MDwise maintains a Preferred Drug List (PDL) that aligns with the Indiana Health Coverage Programs formulary. Drugs excluded by federal statute do not appear on this list for their excluded indication. A physician cannot simply write "medically necessary" on the prescription to override a statutory exclusion. The drug must be prescribed for a covered indication to receive plan benefits.

This distinction matters because tadalafil has FDA approval for two separate conditions: erectile dysfunction and benign prostatic hyperplasia. The same molecule, prescribed for a different diagnosis code, follows entirely different coverage rules.

The BPH Exception: When Tadalafil Gets Covered

Tadalafil 5 mg daily received FDA approval for treating signs and symptoms of BPH in October 2011 [3]. This approval created a pathway for Medicaid coverage that bypasses the ED exclusion entirely.

Clinical Basis for BPH Coverage

The key trials supporting tadalafil for BPH demonstrated statistically significant improvements in International Prostate Symptom Score (IPSS). A 12-week randomized controlled trial (N=1,058) showed tadalafil 5 mg daily improved IPSS by 4.9 points compared to 2.3 points for placebo [4]. The FDA label specifically notes efficacy for lower urinary tract symptoms (LUTS) associated with BPH.

What Your Prescriber Must Document

For MDwise to process a tadalafil claim under the BPH indication, the prescriber needs to:

Submit the claim with ICD-10 code N40.1 (benign prostatic hyperplasia with lower urinary tract symptoms) rather than N52.9 (male erectile dysfunction, unspecified). The prescription should specify tadalafil 5 mg daily, which is the only FDA-approved dose for BPH. Higher doses (10 mg or 20 mg as-needed) are only FDA-approved for ED and will trigger an automatic denial.

Prior Authorization Requirements

Even with a BPH diagnosis, MDwise requires prior authorization for tadalafil. The prescriber must typically demonstrate that the patient has tried or has contraindications to first-line BPH therapies such as tamsulosin or finasteride. Documentation of a prostate-specific antigen (PSA) level, digital rectal exam findings, or urology consultation strengthens the authorization request.

Generic Tadalafil: Cost Without Insurance

Since November 2017, when the first generic tadalafil received FDA approval, retail prices have dropped substantially [5]. For MDwise members who cannot obtain coverage through their plan, cash-pay generic tadalafil represents the most accessible option.

Current Retail Pricing

Generic tadalafil pricing varies by dose and pharmacy:

• Tadalafil 5 mg (30 tablets): $9 to $45 at major chain pharmacies with discount cards
• Tadalafil 10 mg (10 tablets): $15 to $60 depending on pharmacy
• Tadalafil 20 mg (10 tablets): $12 to $55 at most retailers

GoodRx, RxSaver, and similar aggregators frequently show prices below $1 per tablet for the 5 mg and 20 mg strengths. Costco and Mark Cuban's Cost Plus Drugs consistently offer tadalafil at lower price points than traditional pharmacy benefit pricing.

Pill-Splitting Strategy

Many prescribers write tadalafil 20 mg with instructions to split tablets in half for a 10 mg dose. This cuts per-dose cost roughly in half. The tablet has a score line facilitating division. Patients using tadalafil as-needed (rather than daily) may find that 10 purchases per year at $15 to $30 each provides adequate supply.

Brand Cialis vs. Generic Tadalafil: What Differs

Eli Lilly's patent on Cialis expired in September 2018 for the brand product. The generic and brand contain identical active ingredients at identical doses with identical FDA-required bioequivalence standards [6].

Bioequivalence Standards

The FDA requires generic drugs to demonstrate that the rate and extent of absorption fall within 80% to 125% of the reference product's pharmacokinetic parameters [7]. In practice, approved generics typically fall within 3% to 5% of the brand's area under the curve (AUC) and peak concentration (Cmax). There is no clinically meaningful difference between brand Cialis and generic tadalafil.

Why Some Patients Prefer Brand

Anecdotal reports of reduced efficacy with generics exist across all medication categories. These reports lack controlled evidence. A 2019 meta-analysis in the Journal of Sexual Medicine examining PDE5 inhibitor generics found no statistically significant difference in efficacy or adverse event rates compared to branded products [8]. Patients who perceive a difference may be experiencing nocebo effects or batch-to-batch variability within the normal FDA-permitted range.

Alternative Erectile Dysfunction Treatments MDwise May Cover

While PDE5 inhibitors face the federal ED exclusion, other treatments for sexual dysfunction may have different coverage pathways under MDwise.

Vacuum Erection Devices

Durable medical equipment (DME) for ED treatment is not subject to the same statutory exclusion as pharmaceutical products. MDwise covers medically necessary DME with appropriate documentation. A vacuum constriction device (VED) prescribed with diagnosis code N52.9 and supporting documentation of organic erectile dysfunction may be processed as a DME claim rather than a pharmacy claim.

Penile Injection Therapy

Alprostadil (Caverject, Edex) and compounded intracavernosal injection mixtures occupy a gray area in Medicaid coverage. Some states cover injectable ED therapies when oral medications are contraindicated. MDwise members should contact Member Services at 1-800-356-1204 to verify whether alprostadil carries a covered pathway in the current benefit year.

Testosterone Replacement Therapy

If erectile dysfunction stems from documented hypogonadism (total testosterone below 300 ng/dL on two morning specimens), testosterone replacement therapy treats the underlying condition rather than the symptom [9]. MDwise covers testosterone cypionate injections and certain topical formulations for diagnosed hypogonadism with prior authorization. The Endocrine Society Clinical Practice Guidelines recommend against testosterone therapy in men with normal testosterone levels who have ED [10].

How to Appeal an MDwise Denial

If MDwise denies a tadalafil claim, the appeals process follows Indiana Medicaid managed care regulations.

Step 1: Internal Appeal

File a written appeal within 60 days of the denial notice. Include the prescriber's letter of medical necessity, relevant lab work, imaging, or specialty consultation notes, and a clear statement of why the prescribed medication meets coverage criteria. MDwise must respond within 30 days for a standard appeal or 72 hours for an expedited appeal involving urgent medical need.

Step 2: State Fair Hearing

If the internal appeal fails, request a State Fair Hearing through the Indiana Family and Social Services Administration (FSSA). This independent review examines whether MDwise correctly applied Indiana Medicaid policy. The hearing officer can overturn the denial if MDwise misapplied formulary criteria or failed to consider relevant clinical information.

What Strengthens an Appeal

Documentation from a urologist confirming organic ED etiology (vascular, neurogenic, or hormonal) rather than psychogenic ED carries more weight. Objective testing such as nocturnal penile tumescence studies, penile Doppler ultrasound, or hormonal panels provides evidence that the condition has a physiologic basis requiring pharmacotherapy.

Indiana-Specific Access Programs

Several programs available to Indiana residents supplement or bypass Medicaid limitations on ED medications.

Lilly Cares Foundation

Eli Lilly, the original manufacturer of Cialis, operates the Lilly Cares patient assistance program for qualifying low-income patients. Eligibility requires household income at or below 300% of the federal poverty level and lack of prescription drug coverage for the requested medication. MDwise members whose plan excludes Cialis may qualify since the plan effectively provides no coverage for that specific drug [11].

340B Program Pharmacies

Federally Qualified Health Centers (FQHCs) in Indiana that participate in the 340B Drug Pricing Program purchase medications at significantly reduced costs. Some FQHCs pass these savings to uninsured or underinsured patients. Indiana has over 30 FQHC organizations with multiple sites. A patient whose MDwise plan excludes tadalafil could potentially access it at 340B pricing through an FQHC that stocks the medication.

Telehealth Platforms

Direct-to-consumer telehealth services like Hims, Roman, and HealthRX offer generic tadalafil with consultation fees ranging from $0 to $75 and medication costs starting at $0.50 per dose. These services bill patients directly and do not submit claims to MDwise, sidestepping formulary restrictions entirely.

Tadalafil Dosing: What the Evidence Shows

Understanding proper dosing helps patients use tadalafil safely whether obtained through insurance or out-of-pocket.

As-Needed Dosing for ED

The standard starting dose is 10 mg taken prior to anticipated sexual activity, with adjustment to 20 mg or down to 5 mg based on efficacy and tolerability [12]. Tadalafil's 17.5-hour half-life provides a longer window of activity compared to sildenafil (3 to 5 hours) or vardenafil (4 to 5 hours). The maximum recommended frequency is once daily regardless of dose.

Daily Dosing for ED or Combined ED/BPH

Tadalafil 2.5 mg or 5 mg taken once daily provides continuous drug levels that eliminate the need to time doses around sexual activity. The LVHJ trial demonstrated that daily tadalafil 5 mg produced sustained improvements in both IPSS and International Index of Erectile Function (IIEF) scores over 12 weeks [13]. This regimen is particularly appropriate for men who anticipate sexual activity more than twice weekly or who have concurrent BPH symptoms.

Contraindications and Safety

Absolute contraindications include concurrent nitrate therapy (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) due to risk of severe hypotension [14]. Tadalafil should also be avoided within 48 hours of alpha-blocker initiation at full dose. The FDA label warns against use in patients with uncontrolled hypertension (BP above 170/100 mmHg), recent stroke or MI within 90 days, or unstable angina.

What Other Indiana Medicaid Plans Cover

MDwise is one of several managed care entities serving Indiana Medicaid recipients. Coverage policies for ED medications are uniform across these plans because the federal exclusion applies equally to all.

Anthem (HIP and Hoosier Healthwise)

Anthem's Indiana Medicaid formulary mirrors MDwise in excluding PDE5 inhibitors for ED. The BPH pathway for tadalafil 5 mg daily exists under identical prior authorization criteria.

CareSource Indiana

CareSource similarly excludes ED medications under the federal Medicaid statute. No Indiana Medicaid managed care plan covers Cialis or generic tadalafil for erectile dysfunction as a standard benefit.

Marketplace and Employer Plans

Members who transition from MDwise to a Marketplace (ACA exchange) plan or employer-sponsored insurance may find different coverage. Commercial plans are not subject to the Deficit Reduction Act's ED exclusion. Many commercial formularies cover generic tadalafil at Tier 2 or Tier 3 copay levels ($15 to $75 per fill). Members anticipating a coverage transition should verify ED medication coverage during open enrollment.

Cardiovascular Benefits of PDE5 Inhibitors: Emerging Evidence

Beyond sexual function, PDE5 inhibitors show cardiovascular and metabolic effects that may eventually shift coverage conversations.

Heart Failure Data

A 2022 systematic review in Circulation: Heart Failure (N=12,843 across 36 studies) found that PDE5 inhibitors improved cardiac output, reduced pulmonary vascular resistance, and enhanced exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF) [15]. Tadalafil's longer half-life made it the most-studied agent in this class for cardiovascular indications.

Metabolic Effects

Preclinical and early clinical data suggest PDE5 inhibition improves insulin sensitivity and endothelial function. A randomized trial in Diabetes Care (N=20) showed that tadalafil 20 mg daily for 12 weeks reduced fasting insulin by 33% in men with type 2 diabetes and erectile dysfunction [16]. These findings remain preliminary but suggest that the drug class may have broader therapeutic applications beyond sexual function.

The American Urological Association guidelines on ED management (2018) recommend PDE5 inhibitors as first-line pharmacotherapy for erectile dysfunction, noting their favorable safety profile and high efficacy rates of 60% to 70% across all-comers [17].